当前位置:
X-MOL 学术
›
Cancer Res.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Expanding the Full Potential of Liquid Biopsies for Lung Cancer Patients
Cancer Research ( IF 11.2 ) Pub Date : 2022-08-16 , DOI: 10.1158/0008-5472.can-22-2109 Christian Rolfo 1 , Umberto Malapelle 2 , Alessandro Russo 3
Cancer Research ( IF 11.2 ) Pub Date : 2022-08-16 , DOI: 10.1158/0008-5472.can-22-2109 Christian Rolfo 1 , Umberto Malapelle 2 , Alessandro Russo 3
Affiliation
In recent years, there has been tremendous therapeutic progress for advanced lung cancer, leading to the identification of a multitude of therapeutic targets and significantly expanding the list of potential target genes to be tested. However, precision oncology requires knowledge of the exact biology of the tumor through sequencing of the cancer genome, which is hampered by limited tissue availability in thoracic malignancies. Liquid biopsy, namely plasma cell-free DNA (cfDNA) analysis, has expanded these opportunities and is now firmly established in the diagnostic algorithm of patients with lung cancer with metastatic disease. However, the full potential of this powerful tool has been largely underexplored. In this issue of Cancer Research, Nair and colleagues provide evidence of the clinical utility of bronchoalveolar lavage (BAL) cfDNA profiling through an ultra-deep next-generation sequencing approach. The study findings support further development of BAL cfDNA analysis for tumor genotyping, besides the current gold standard sources (tissue and plasma), as a complementary tool in patients undergoing diagnostic bronchoscopy for tumor diagnosis and/or rebiopsy, increasing the success rates of genomic analyses. In addition, BAL cfDNA profiling might represent an important diagnostic tool in early-stage lung cancer, outperforming plasma cfDNA in stage I–II and detecting field cancerization signs, potentially identifying tumors before their clinical appearance. Further studies should confirm the full potential of BAL cfDNA profiling in lung cancer and its place in the large family of liquid biopsies.See related article by Nair et al., p. 2838
中文翻译:
充分发挥液体活检对肺癌患者的潜力
近年来,晚期肺癌的治疗取得了巨大进展,导致了多种治疗靶点的确定,并显着扩大了待测试的潜在靶基因的范围。然而,精准肿瘤学需要通过癌症基因组测序来了解肿瘤的确切生物学知识,而胸部恶性肿瘤的组织可用性有限,这阻碍了这一点。液体活检,即血浆游离 DNA (cfDNA) 分析,扩大了这些机会,现已牢固地确立在患有转移性疾病的肺癌患者的诊断算法中。然而,这一强大工具的全部潜力在很大程度上尚未得到充分开发。在本期《癌症研究》中,Nair 及其同事通过超深下一代测序方法提供了支气管肺泡灌洗 (BAL) cfDNA 分析的临床实用性证据。研究结果支持进一步开发用于肿瘤基因分型的 BAL cfDNA 分析,除了当前的金标准来源(组织和血浆)之外,作为接受诊断性支气管镜检查以进行肿瘤诊断和/或再活检的患者的补充工具,提高基因组分析的成功率。此外,BAL cfDNA 分析可能是早期肺癌的重要诊断工具,在 I-II 期优于血浆 cfDNA,可检测现场癌化迹象,有可能在肿瘤临床出现之前识别肿瘤。进一步的研究应证实 BAL cfDNA 分析在肺癌中的全部潜力及其在液体活检大家族中的地位。请参阅 Nair 等人的相关文章,第 17 页。2838
更新日期:2022-08-16
中文翻译:
充分发挥液体活检对肺癌患者的潜力
近年来,晚期肺癌的治疗取得了巨大进展,导致了多种治疗靶点的确定,并显着扩大了待测试的潜在靶基因的范围。然而,精准肿瘤学需要通过癌症基因组测序来了解肿瘤的确切生物学知识,而胸部恶性肿瘤的组织可用性有限,这阻碍了这一点。液体活检,即血浆游离 DNA (cfDNA) 分析,扩大了这些机会,现已牢固地确立在患有转移性疾病的肺癌患者的诊断算法中。然而,这一强大工具的全部潜力在很大程度上尚未得到充分开发。在本期《癌症研究》中,Nair 及其同事通过超深下一代测序方法提供了支气管肺泡灌洗 (BAL) cfDNA 分析的临床实用性证据。研究结果支持进一步开发用于肿瘤基因分型的 BAL cfDNA 分析,除了当前的金标准来源(组织和血浆)之外,作为接受诊断性支气管镜检查以进行肿瘤诊断和/或再活检的患者的补充工具,提高基因组分析的成功率。此外,BAL cfDNA 分析可能是早期肺癌的重要诊断工具,在 I-II 期优于血浆 cfDNA,可检测现场癌化迹象,有可能在肿瘤临床出现之前识别肿瘤。进一步的研究应证实 BAL cfDNA 分析在肺癌中的全部潜力及其在液体活检大家族中的地位。请参阅 Nair 等人的相关文章,第 17 页。2838